- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00868985
Effects of Oral PEG 3350 on Electrolyte Balance
Effects of Oral PEG 3350 on the Electrolyte Balance in Patient Volunteers With Chronic Constipation:Pharmacokinetic Evaluation
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Timisoara, Romania, Ro-300244
- IFE Human Pharmacology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subjects written informed consent must be obtained prior to inclusion.
Male and female patients between 18 and 70 years of age with confirmed chronic constipation after the run-in period; this is defined as patients who have recorded in their diaries less than 3 bowel motions/week plus one of the following symptoms:
Straining during at least 25% of defecations Lumpy or hard stools with at least 25% of defecations Sense of incomplete evacuation with at least 25% of defecation Sensation of ano-rectal blockage with at least 25% of defecation Manula manoeuvres of facilitate at least 25% of defecation
- Willing and able to follow the entire procedure and to comply with the study instructions.
- For the subgroup of patient volunteers taking ACE-inhibitors (36 subjects): A history of hypertension, with blood pressure controlled to acceptable levels by a stable regimen of ACE-inhibitors.
Exclusion Criteria:
- Participation in a clinical research study involving investigational drugs or dosage forms within the previous 3 months.
- Subjects who have previously been enrolled in this study.
- Subjects who are currently or have a history of abuse of alcohol, non-medical drugs, medicinal drugs or other substance abuse eg solvents.
- Major surgery in within the last 12 months.
- Malignant tumors within the last 5 years.
- Uncontrolled blood pressure or terminal cardiac, liver and/or kidney diseases.
- Clinical relevant acute gastrointestinal tract disease, including evidence of intestinal perforation or obstruction, paralytic ileus, toxic megacolon, severe inflammatory conditions.
- Acute urinary tract conditions, including cystitis.
- Patients with diagnosis or evidence of the following diseases: Hypothyroidism, diabetes mellitus, porphyria, pituitary gland insufficiency, pheochromocytoma, glucagonoma, neurological diseases (eg Hirschprung disease, neurofibromatosis, Chagas disease, stroke, autonomous neuropathy, intestinal pseudoobstruction, Multiple sclerosis, medullar injury, Parkinson disease, Shy-Drager syndrome), collagenosis, vasculitis, myopathy (e.g. sclerodermatitis, amyloidosis, dermatomyositis), intoxication with heavy metals (e.g. Pb, As, Hg)
Concomitant medication:
- Use of any oral purgatives/laxatives and prokinetics within the last 14 days prior to dosing.
- Use of any opioids, anti-cholinergics, tricyclic anti-depressants, MAOIs, Fe preparations, within the 4 weeks prior to dosing.
- Use of any Ca-antagonists, Beta-blockers or diuretics within the last 4 weeks prior to dosing.
- other medication which in the opinion of the Investigator could interfere with the principal function of the GI tract.
- Subject unable to provide written consent.
- Failure to satisfy the Investigator of fitness to participate for any other reason, including suspected non-compliance.
- Women of childbearing potential, who are not using and not willing to use medically reliable methods of contraception for the entire study duration, unless they are surgically sterilised/hysterectomised or any other criteria considered sufficiently reliable by the Investigator in individual cases.
- Patients with electrolytes disturbances or clinical signs of dehydration.
- Positive test at screening for HIV or hepatitis.
- Any clinically significant abnormal test results.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: PEG 3350 plus electrolytes
Patients were dosed with PEG 3350 with electrolytes
|
Each patient was treated with PEG 3350 with electrolytes for 10 days at a dose of either one, two or three sachets per day.
|
EXPERIMENTAL: PEG 3350 without electrolytes
Patients were dosed with PEG 3350 without electrolytes
|
Each patient was treated with PEG 3350 for 10 days at a dose of either one, two or three sachets per day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Electrolyte profile in blood, urine and faeces, serum osmolality and effect on the renin/aldosterone ratio
Time Frame: Ten days
|
Ten days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Amount of PEG 3350 in plasma, urine and faeces
Time Frame: Ten days
|
Ten days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Rodica Cinca, MD, IFE Human Pharmacology
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PEG-01/2007(ELE)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Constipation
-
usMIMA S.L.CompletedConstipation | Constipation Chronic Idiopathic | Constipation; NeurogenicSpain, United Kingdom
-
SK Life Science, Inc.CompletedChronic Constipation | Functional ConstipationUnited States
-
AbbVieIronwood Pharmaceuticals, Inc.RecruitingFunctional Constipation (FC) | Chronic Idiopathic Constipation (CIC)United States, United Kingdom, Bulgaria, Netherlands
-
Cairo UniversityUnknownChronic Idiopathic Constipation | Functional ConstipationEgypt
-
Air Force Military Medical University, ChinaRecruitingChronic ConstipationChina
-
Yokohama City UniversityRecruiting
-
TakedaThe Organization of Teratology Information SpecialistsRecruiting
-
TakedaUC San Diego Human Milk Research BiorepositoryRecruiting
-
International University of Health and WelfareTerminated
-
Astellas Pharma IncCompleted
Clinical Trials on PEG 3350 plus electrolytes
-
BayerCompleted
-
Temple UniversityCompletedColon CancerUnited States
-
Indiana UniversityRecruiting
-
Fundación Pública Andaluza para la gestión de la...Unknown
-
NorgineCompleted
-
Instituto Nacional de Ciencias Medicas y Nutricion...CompletedBowel Preparation for ColonoscopyMexico
-
ColonaryConcepts LLCCompleted
-
University of MichiganRecruitingIrritable Bowel Syndrome Characterized by ConstipationUnited States
-
Children's Hospital of PhiladelphiaFood and Drug Administration (FDA)Recruiting
-
Institute of Medical Sciences and SUM HospitalNot yet recruitingFunctional Constipation | Constipation - Functional | Constipation Chronic Idiopathic | Fecal Impaction | Pediatric Functional ConstipationIndia